High-throughput kinase profiling as a platform for drug discovery

Nature Reviews. Drug Discovery
David M GoldsteinPatrick Zarrinkar

Abstract

To fully exploit the potential of kinases as drug targets, novel strategies for the efficient discovery of inhibitors are required. In contrast to the traditional, linear process of inhibitor discovery, high-throughput kinase profiling enables a parallel approach by interrogating compounds against hundreds of targets in a single screen. Compound potency and selectivity are determined simultaneously, providing a choice of targets to pursue that is guided by the quality of lead compounds available, rather than by target biology alone.

References

Sep 23, 2000·Nature·P Carmeliet, R K Jain
Jul 27, 2001·Current Opinion in Chemical Biology·P R CaronM A Murcko
Mar 16, 2002·Nature Structural Biology·Christopher PargellisJohn Regan
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Aug 28, 2002·The Journal of Biological Chemistry·Jennifer StamosCharles Eigenbrot
Nov 1, 2003·Science·Paul S ChangelianDominic C Borie
Mar 17, 2004·Biochimica Et Biophysica Acta·Michal ViethHorst Hemmerle
Jun 11, 2004·Journal of Medicinal Chemistry·Paolo PevarelloMartha A Warpehoski
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Aug 24, 2004·Combinatorial Chemistry & High Throughput Screening·B LiN Gray
Jun 25, 2005·The Journal of Biological Chemistry·Stéphane BachLaurent Meijer
Jul 28, 2005·Proceedings of the National Academy of Sciences of the United States of America·Todd A CarterDavid J Lockhart
Sep 24, 2005·Current Topics in Medicinal Chemistry·David M Goldstein, Tobias Gabriel
Nov 8, 2005·Proceedings of the National Academy of Sciences of the United States of America·Katharine A WhartenbyDonald Small
Dec 13, 2005·Bioorganic & Medicinal Chemistry Letters·Nicola M HeronSiân Rowsell
Feb 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Gromoslaw A SmolenDaniel A Haber
Feb 24, 2006·Proceedings of the National Academy of Sciences of the United States of America·Jonathan S MelnickJeremy S Caldwell
Mar 25, 2006·Nature Reviews. Cancer·Klaus Strebhardt, Axel Ullrich
May 12, 2006·Journal of Medicinal Chemistry·Tina MorwickCharles L Cywin
May 12, 2006·The New England Journal of Medicine·Ellin BermanNicholas P Sauter
May 26, 2006·Nature·John D BensonChristoph Lengauer
May 26, 2006·Nature·Judith S Sebolt-Leopold, Jessie M English
Jun 20, 2006·Nature Chemical Biology·Yi Liu, Nathanael S Gray
Aug 22, 2006·Nature Chemical Biology·Jonathan B FitzgeraldPeter K Sorger
Aug 25, 2006·The Journal of Biological Chemistry·Phillip P KnowlesNeil Q McDonald
Sep 19, 2006·Nature Neuroscience·Wanli W SmithChristopher A Ross
Nov 3, 2006·Nature Reviews. Drug Discovery·Thomas RückleChristian Rommel
Nov 17, 2006·Nature Chemical Biology·Ian Collins, Paul Workman
Dec 13, 2006·Nature Reviews. Drug Discovery·Alexander KambChristoph Lengauer
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keith T Flaherty
Feb 3, 2007·The New England Journal of Medicine·Ayalew Tefferi
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Mark G ManfrediChristopher F Claiborne
Apr 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Archie N TseGary K Schwartz
Apr 26, 2007·Nature Reviews. Cancer·Thomas ForceRichard A Van Etten
May 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Nupam P MahajanYoung E Whang
May 25, 2007·Nature Reviews. Cancer·Henk M W Verheul, Herbert M Pinedo
Jun 1, 2007·Proceedings of the National Academy of Sciences of the United States of America·Leonard BuckbinderMei Li
Jun 15, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaap Verweij, Maja de Jonge
Jun 27, 2007·Proceedings of the National Academy of Sciences of the United States of America·Mansuo L HayashiSusumu Tonegawa
Jul 11, 2007·Molecular Cancer Therapeutics·Travis L Schmit, Nihal Ahmad

❮ Previous
Next ❯

Citations

May 10, 2011·Cancer Chemotherapy and Pharmacology·Kenneth KolinskyBrian Higgins
Jun 24, 2008·Purinergic Signalling·Shripad S Bhagwat
Jul 2, 2009·Journal of Chemical Biology·Lynette A Smyth, Ian Collins
Sep 22, 2010·Journal of Chemical Information and Modeling·Michal Brylinski, Jeffrey Skolnick
Mar 15, 2012·Journal of Chemical Information and Modeling·Satoshi NiijimaYasushi Okuno
Dec 25, 2012·Journal of Chemical Information and Modeling·Stephan C Schürer, Steven M Muskal
Jul 16, 2011·Journal of Medicinal Chemistry·W Patrick WaltersMark A Murcko
Dec 6, 2012·Journal of Medicinal Chemistry·Dilyana DimovaJürgen Bajorath
Mar 9, 2010·Journal of Medicinal Chemistry·Thomas P MathewsTimothy L Macdonald
Oct 6, 2009·Nature Biotechnology·Kazuishi KubotaSteven P Gygi
Mar 11, 2011·Nature Biotechnology·Monya Baker, Laura DeFrancesco
Nov 1, 2011·Nature Biotechnology·Theonie AnastassiadisJeffrey R Peterson
Feb 8, 2013·Nature Medicine·Louis H MillerThomas E Wellems
Aug 20, 2010·Nature Reviews. Cancer·Walter Kolch, Andrew Pitt
Sep 2, 2009·Nature Reviews. Drug Discovery·Robert A CopelandVictoria M Richon
Jul 31, 2010·Nature Reviews. Drug Discovery·Klaus Strebhardt
Nov 11, 2011·Marine Drugs·Danielle SkropetaAna Zivanovic
Jun 7, 2014·Annual Review of Biochemistry·Micah J Niphakis, Benjamin F Cravatt
Jan 30, 2014·Journal of Molecular Graphics & Modelling·Rahul P GangwalAbhay T Sangamwar
Jul 7, 2014·Nature Chemical Biology·Daniel A BachovchinTodd R Golub
Jul 30, 2014·Proceedings of the National Academy of Sciences of the United States of America·Julius SemenasJenny L Persson
Jul 19, 2013·Future Medicinal Chemistry·Kristin J Labby, Sylvie Garneau-Tsodikova
Mar 8, 2011·Nature Chemical Biology·Xianming DengNathanael S Gray
Nov 7, 2012·Expert Opinion on Therapeutic Patents·Xianming DengNathanael S Gray
Feb 26, 2010·Expert Opinion on Therapeutic Patents·Hervé GalonsLaurent Meijer
Jun 7, 2013·Expert Opinion on Drug Discovery·Shivaputra A PatilDuane D Miller
Jan 18, 2011·Expert Opinion on Investigational Drugs·Rina Barouch-Bentov, Karsten Sauer
Sep 14, 2012·Expert Opinion on Drug Discovery·Paul Bamborough
Jan 24, 2013·Experimental Hematology·Violeta YuRenee Emkey
May 15, 2012·Trends in Pharmacological Sciences·Byoung Dae LeeTed M Dawson
Aug 6, 2011·Journal of Pharmaceutical and Biomedical Analysis·S ChandranK Raghavan
May 25, 2011·Drug Discovery Today·Scott J LusherJacob de Vlieg
Dec 17, 2015·Pharmacogenomics·Aik Choon TanPaul H Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.